Skip to content

Outcome of Vitamin D supplementation alongwith the standard treatment in Lymphoma Patients.

Evaluation of Vitamin D Supplementation in Affecting the Outcome of Newly Diagnosed Patients with Lymphoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/018211
Enrollment
160
Registered
2019-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C847- Anaplastic large cell lymphoma, ALK-negative Health Condition 2: C846- Anaplastic large cell lymphoma, ALK-positive Health Condition 3: C865- Angioimmunoblastic T-cell lymphoma Health Condition 4: C864- Blastic NK-cell lymphoma Health Condition 5: C837- Burkitt lymphoma Health Condition 6: C826- Cutaneous follicle center lymphoma Health Condition 7: C84A- Cutaneous T-cell lymphoma, unspecified Health Condition 8: C825- Diffuse follicle center lymphoma Health Condition 9

Interventions

Intervention1: Vitamin D Intramascular injection: Vitamin D supplementation in newly diagnosed lymphoma patients,if found deficient(less than 12 ng/ml) Control Intervention1: Not applicable: Not appli

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)All newly diagnosed patients with Hodgkin Lymphoma(HL) and Non Hodgkinâ??s Lymphoma(NHL) 2) Age group (7-80 yrs)

Exclusion criteria

Exclusion criteria: 1) Patients who are not planned for any anticancer treatment. 2) Patients previously treated with chemotherapy/radiotherapy/surgery. 3)Patients having renal stone or Hypercalcemia ( more than 12 mg/dl) will not be given supplementation 4) Female patients with pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
a)To study the association of baseline vitamin D level with Overall Response Rate(ORR) in patients with newly diagnosed lymphoma. b)To study the effect of vitamin D supplementation on Overall Response Rate (ORR) in the vitamin D deficient patients with newly diagnosed lymphoma. Timepoint: August 2018 to May 2020

Secondary

MeasureTime frame
a) To study the association of baseline vitamin D levels with Event Free Survival (EFS) in patients with newly diagnosed lymphoma. b) To study and compare chemotherapy toxicities in newly diagnosed lymphoma patients with and without vitamin D deficiency. Timepoint: August 2018 to May 2020

Countries

India

Contacts

Public ContactSmita Kayal

JIPMER

kayalsmita@gmail.com7598118439

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026